Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume – Still a Buy?

Elekta AB (OTCMKTS:EKTAY – Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 6,765 shares were traded during trading, an increase of 125% from the previous session’s volume of 3,000 shares.The stock last traded at $5.76 and had previously closed at $5.83.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

Get Elekta alerts:

Get Our Latest Research Report on EKTAY

Elekta Price Performance

The business has a fifty day simple moving average of $5.15 and a two-hundred day simple moving average of $5.72. The company has a current ratio of 0.87, a quick ratio of 0.68 and a debt-to-equity ratio of 0.47. The stock has a market cap of $2.17 billion, a PE ratio of -36.78 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY – Get Free Report) last posted its quarterly earnings results on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The company had revenue of $521.00 million for the quarter. Research analysts forecast that Elekta AB will post 0.43 earnings per share for the current year.

Elekta Company Profile

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Recommended Stories

• Five stocks we like better than Elekta
• MarketBeat Week in Review – 08/17 – 08/21
• Blueprint for a Boom: SEC Clears the Crypto Runway
• Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
• Advance Auto Parts Plunged, But Its Turnaround Is Still Working

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.